Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, 610041, Chengdu, China.
Department of Endocrinology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Hubei, 441000, Xiangyang , China.
BMC Endocr Disord. 2021 May 1;21(1):90. doi: 10.1186/s12902-021-00756-z.
Hypercalcemia associated with acromegaly is mostly parathyroid hormone (PTH)-dependent, being caused by parathyroid hyperplasia or adenoma, which are common in individuals with multiple endocrine adenomatosis-1 (MEN-1). The rare occurrence of non-PTH-dependent hypercalcemia associated with acromegaly is attributable to complex factors involving increased intestinal calcium absorption, enhanced bone calcium release, and reduced urinary calcium elimination. Although patients with acromegaly often have mild hyperphosphatemia and hypercalciuria, clinically significant hypercalcemia is extremely rare.
Here we present a case of non-PTH-dependent hypercalcemia associated with a growth hormone- (GH) and prolactin- (PRL) co-secreting pituitary macroadenoma. A 37-year-old Chinese man presented with a 6-year history of increasing ring and shoe sizes and was referred to the West China Hospital of Sichuan University for treatment of acromegaly. Pituitary magnetic resonance imaging (MRI) showed a 2.0 × 1.7 × 1.9 cm macroadenoma. Laboratory examinations revealed high serum concentrations of GH and PRL with mild hypercalcemia, hyperphosphatemia, hypercalciuria, inhibited PTH concentration, and increased bone turnover markers. Administration of cabergoline together with somatostatin resulted in sharp decreases in his GH, PRL, and serum and urinary calcium concentrations. These values were further reduced 5 months later and his PTH and bone turnover markers gradually returned to within the normal range.
Mild hyperphosphatemia and hypercalciuria are common in individuals with acromegaly and deserve attention because they may contribute to osteoporosis and urolithiasis. However, overt hypercalcemia is rare in such individuals. It is usually attributable to a coexisting parathyroid hyperplasia or adenoma, rarely being non-PTH-dependent. In such cases, the hypercalcemia is attributable to excessive PRL and hypogonadism and reverses with remission of acromegaly.
与肢端肥大症相关的高钙血症大多依赖甲状旁腺激素 (PTH),这是由甲状旁腺增生或腺瘤引起的,在多发性内分泌腺瘤病 1 型 (MEN-1) 患者中很常见。与肢端肥大症相关的罕见非 PTH 依赖性高钙血症归因于涉及增加肠道钙吸收、增强骨钙释放和减少尿钙排泄的复杂因素。尽管肢端肥大症患者常伴有轻度高磷血症和高钙尿症,但临床上显著的高钙血症极为罕见。
本文报道了一例生长激素 (GH) 和催乳素 (PRL) 共分泌垂体大腺瘤相关的非 PTH 依赖性高钙血症。一名 37 岁中国男性,以进行性鞋码增大 6 年为主诉,转至四川大学华西医院治疗肢端肥大症。垂体磁共振成像 (MRI) 显示 2.0×1.7×1.9cm 大腺瘤。实验室检查发现血清 GH 和 PRL 浓度升高,伴有轻度高钙血症、高磷血症、高钙尿症、PTH 浓度抑制和骨转换标志物增加。卡麦角林联合生长抑素治疗后,他的 GH、PRL 和血清及尿钙浓度明显下降。5 个月后,这些值进一步降低,他的 PTH 和骨转换标志物逐渐恢复正常范围。
肢端肥大症患者常伴有轻度高磷血症和高钙尿症,应引起重视,因为它们可能导致骨质疏松症和尿路结石。然而,此类患者显性高钙血症罕见,通常归因于同时存在的甲状旁腺增生或腺瘤,很少是非 PTH 依赖性的。在这种情况下,高钙血症归因于过多的 PRL 和性腺功能减退,随着肢端肥大症的缓解而逆转。